We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Read MoreHide Full Article
Key Takeaways
Abbott's Q3 adjusted earnings met estimates despite a revenue miss on strong year-over-year growth.
Tariffs and weaker Diagnostics sales in China narrowed margins and curbed investor enthusiasm.
Diversified growth in Medical Devices and Nutrition supports Abbott's resilience amid trade headwinds.
Shares of Abbott (ABT - Free Report) have edged up 0.7% since the company’s third-quarter 2025 earnings release on Oct. 15, 2025. The company reported a strong year-over-year increase in adjusted earnings and revenues. Earnings came in line with the Zacks Consensus Estimate, while revenues missed the same. Global Core Laboratory Diagnostics sales were impacted by challenging market conditions in China, including the impact of volume-based procurement programs. External pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains.
Let’s delve deeper.
Abbott Share Comparison Since Q3 Earnings Release
Image Source: Zacks Investment Research
Since its earnings release, shares of Abbott have underperformed the industry and the sector’s gain of 0.7% and 0.2%, respectively. The S&P 500 index, which dipped 0.1% during the period, also stayed ahead of ABT stock. The company’s archrivals like Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) registered share price improvements of 1.6% and 0.5%, respectively, during the said period.
Segmental Performance Synopsis
Abbott’s third-quarter 2025 results showed broad-based growth across most segments. Established Pharmaceuticals rose 7.5% (up 7.1% organically) with emerging markets up 11.1%. Medical Devices grew 14.8% (up 12.5% organically), led by Diabetes Care (up 16.2%), Structural Heart (up 11.3%), Heart Failure (up 12.1%) and strong Electrophysiology, Rhythm Management, and Neuromodulation sales. Nutrition sales increased 4.2% (up 4% organically), driven by Ensure and Glucerna.
Diagnostics declined 6.6% (down 7.8% organically) though ex-COVID organic sales were flat. Core and Molecular Diagnostics saw modest growth, while Rapid Diagnostics fell 27.7%, partially offset by Point of Care ( up 7.8%).
Tariffs Impact Margins
Abbott Laboratories' growth trajectory in 2025 faces challenges due to escalating tariffs, particularly from U.S. trade policies. In the third quarter, gross profit rose 6% year over year. However, gross margin contracted 46 basis points (bps) to 55.4% due to tariff impacts. These tariffs are particularly consequential given that Abbott’s product portfolio, ranging from infant nutrition to advanced medical devices, relies heavily on global production and distribution networks.
Meanwhile, selling, general and administration expenses rose 5.4% year over year. Research and development expenses rose 7.4% year over year. The company reported adjusted operating profit growth of 6.4% year over year. The adjusted operating margin contracted 11 bps to 21.8%.
Defensive Strategy Might Improve Situation
While the trade policy environment introduces complexity, Abbott’s management remains confident about the company’s ability to weather the storm. The company is leveraging its diversified portfolio, strong brand recognition and robust pipeline of new products, including nearly $0.5 billion in sales from recent launches, to sustain growth despite tariff pressure.
Investments in U.S. manufacturing and R&D facilities aim to strengthen supply chain resilience, while broad-based demand across Medical Devices, Nutrition and Established Pharmaceuticals provides a buffer against geopolitical and market uncertainties. Management continues to guide high single-digit organic sales growth and double-digit EPS growth, reflecting disciplined execution and innovation-driven resilience.
ABT's 2025 Financial Guidance
For the full year, Abbott expects adjusted diluted EPS to be in the range of $5.12 -$5.18 (earlier $5.10-$5.20). Full-year organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0% (same as earlier). When including COVID-19 testing-related sales, organic sales growth is forecasted to be 6-7% (unchanged).
Long-Term Potential Hindered by Short-Term Weakness
Abbott is currently trading below its 50-day and 200-day simple moving averages (SMA), indicating short-term bearishness, while long-term trends remain under pressure amid ongoing macroeconomic complexities.
ABT's 50 & 200-Day SMA
Image Source: Zacks Investment Research
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 23.10X, a premium to the industry average of 20.75X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 16.46. However, Boston Scientific, with a current P/E of 30.02X, appears more stretched.
Image Source: Zacks Investment Research
Our Take: Hold Now
Despite its adaptive strategies, Abbott's stock price does not reflect the company’s underlying strength. The subdued market reaction to its third-quarter earnings and revenue growth suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive top-line performance in the third quarter boosted investor sentiment, barring Diagnostics, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Image: Bigstock
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Key Takeaways
Shares of Abbott (ABT - Free Report) have edged up 0.7% since the company’s third-quarter 2025 earnings release on Oct. 15, 2025. The company reported a strong year-over-year increase in adjusted earnings and revenues. Earnings came in line with the Zacks Consensus Estimate, while revenues missed the same. Global Core Laboratory Diagnostics sales were impacted by challenging market conditions in China, including the impact of volume-based procurement programs. External pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains.
Let’s delve deeper.
Abbott Share Comparison Since Q3 Earnings Release
Image Source: Zacks Investment Research
Since its earnings release, shares of Abbott have underperformed the industry and the sector’s gain of 0.7% and 0.2%, respectively. The S&P 500 index, which dipped 0.1% during the period, also stayed ahead of ABT stock. The company’s archrivals like Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) registered share price improvements of 1.6% and 0.5%, respectively, during the said period.
Segmental Performance Synopsis
Abbott’s third-quarter 2025 results showed broad-based growth across most segments. Established Pharmaceuticals rose 7.5% (up 7.1% organically) with emerging markets up 11.1%. Medical Devices grew 14.8% (up 12.5% organically), led by Diabetes Care (up 16.2%), Structural Heart (up 11.3%), Heart Failure (up 12.1%) and strong Electrophysiology, Rhythm Management, and Neuromodulation sales. Nutrition sales increased 4.2% (up 4% organically), driven by Ensure and Glucerna.
Diagnostics declined 6.6% (down 7.8% organically) though ex-COVID organic sales were flat. Core and Molecular Diagnostics saw modest growth, while Rapid Diagnostics fell 27.7%, partially offset by Point of Care ( up 7.8%).
Tariffs Impact Margins
Abbott Laboratories' growth trajectory in 2025 faces challenges due to escalating tariffs, particularly from U.S. trade policies. In the third quarter, gross profit rose 6% year over year. However, gross margin contracted 46 basis points (bps) to 55.4% due to tariff impacts. These tariffs are particularly consequential given that Abbott’s product portfolio, ranging from infant nutrition to advanced medical devices, relies heavily on global production and distribution networks.
Meanwhile, selling, general and administration expenses rose 5.4% year over year. Research and development expenses rose 7.4% year over year. The company reported adjusted operating profit growth of 6.4% year over year. The adjusted operating margin contracted 11 bps to 21.8%.
Defensive Strategy Might Improve Situation
While the trade policy environment introduces complexity, Abbott’s management remains confident about the company’s ability to weather the storm. The company is leveraging its diversified portfolio, strong brand recognition and robust pipeline of new products, including nearly $0.5 billion in sales from recent launches, to sustain growth despite tariff pressure.
Investments in U.S. manufacturing and R&D facilities aim to strengthen supply chain resilience, while broad-based demand across Medical Devices, Nutrition and Established Pharmaceuticals provides a buffer against geopolitical and market uncertainties. Management continues to guide high single-digit organic sales growth and double-digit EPS growth, reflecting disciplined execution and innovation-driven resilience.
ABT's 2025 Financial Guidance
For the full year, Abbott expects adjusted diluted EPS to be in the range of $5.12 -$5.18 (earlier $5.10-$5.20). Full-year organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0% (same as earlier). When including COVID-19 testing-related sales, organic sales growth is forecasted to be 6-7% (unchanged).
Long-Term Potential Hindered by Short-Term Weakness
Abbott is currently trading below its 50-day and 200-day simple moving averages (SMA), indicating short-term bearishness, while long-term trends remain under pressure amid ongoing macroeconomic complexities.
ABT's 50 & 200-Day SMA
Image Source: Zacks Investment Research
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 23.10X, a premium to the industry average of 20.75X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 16.46. However, Boston Scientific, with a current P/E of 30.02X, appears more stretched.
Image Source: Zacks Investment Research
Our Take: Hold Now
Despite its adaptive strategies, Abbott's stock price does not reflect the company’s underlying strength. The subdued market reaction to its third-quarter earnings and revenue growth suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive top-line performance in the third quarter boosted investor sentiment, barring Diagnostics, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Abbott currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.